Realistically, this synergistic approach using NHE1 inhibitors as co-adjuvants to established chemotherapeutic drugs, could arguably be effective in augmenting the targeted treatment of the HER2-positive subtype of breast cancer as well. Here, ERBB2 is linked to breast cancer.